Dr Reddy’s Laboratories Ltd Q2 FY26: ₹8,828 Cr Quarterly Sales, ₹1,337 Cr PAT, EPS ₹16.14 — Big Pharma, Bigger Headaches, Solid Math
1. At a Glance – Blink and You’ll Miss the Numbers
Dr Reddy’s Laboratories Ltd is currently sitting at a market capitalisation of ₹98,528 Cr, trading around ₹1,180, pretending to be boring while casually posting ₹8,828 Cr in quarterly revenue and ₹1,337 Cr in quarterly PAT. Stock P/E is 17.1, ROCE is a healthy 22.7%, ROE clocks 18%, and debt is at a very pharma-appropriate ₹5,854 Cr with a modest 0.16 debt-to-equity. Three-month returns are negative (-3.94%), six-month returns are worse (-5.26%), which basically means the stock is sulking despite doing its homework properly.
Operating margins are holding at 23%, dividend yield is 0.69% (just enough to remind you it exists), and EPS for the latest quarter stands at ₹16.14. Multiply that by four (because yes, these are Quarterly Results, lock it here), and the annualised EPS lands at ₹64.56.
In short: fundamentals are flexing quietly, the market is yawning loudly, and long-term investors are arguing in WhatsApp groups. Curious already?
2. Introduction – The Calm, Calculated Chaos of Dr Reddy
Dr Reddy’s Laboratories is that student in class who never tops every exam but always ends up doing well in life. Founded on science, discipline, and a borderline obsessive relationship with regulatory filings, the company has evolved into a global pharmaceutical powerhouse with presence across APIs, generics, biosimilars, and niche formulations.
Unlike some peers who shout growth stories from rooftops, Dr Reddy prefers spreadsheets, FDA filings, and consistent execution. Its business is spread across geographies like the US, India, Russia, and emerging markets, ensuring that when one region sneezes, the company doesn’t immediately catch pneumonia.
What makes Dr Reddy interesting is not flashy innovation but repeatability. File ANDAs, launch generics, sweat assets, keep costs in check, rinse, repeat. Over time, this boring discipline has resulted in 14% sales CAGR over 3 years and 38% profit CAGR over 3 years.
But the road is never smooth in pharma. USFDA inspections, Form-483s, CRLs, pricing pressure, and regulatory chess games keep the adrenaline flowing. The question is: does Dr Reddy thrive in chaos, or merely survive it?
3. Business Model – WTF Do They Even Do?
Let’s break it down like explaining to a lazy but intelligent investor who skipped biology class.
Dr Reddy has three main engines:
Global Generics (≈83% of FY22 revenue) This is the cash cow. Over 400 generic drugs, sold across regulated and semi-regulated markets. The magic sauce is vertical integration: Dr Reddy often makes its own APIs, formulates them, files regulatory approvals, and then sells the final pill. Nervous system drugs (14%), gastrointestinal (13%), and anti-infectives (10%) dominate here. In FY22, the company filed 7 new ANDAs with the US FDA.
Pharmaceutical Services & Active Ingredients (≈14%) APIs are the boring backbone of pharma, and Dr Reddy is one of the world’s largest manufacturers. In FY22 alone, 139 DMFs were filed globally, including 10 in the US. Cardiovascular, anti-infective, and pain management APIs dominate this segment.
Proprietary Products & Others (≈2%) Small in revenue, big in ambition. This includes differentiated formulations and the biotech arm Aurigene, which focuses on oncology and inflammation. High risk, high science, low current contribution.
In short: Dr Reddy sells a lot of pills, makes many of its own ingredients, experiments cautiously, and hates wasting capital. Efficient? Yes. Exciting? Depends on your definition of excitement.
4. Financials Overview – The Quarterly Scorecard (No Guesswork)
Result Type Locked: QUARTERLY RESULTS Annualised EPS = Latest Quarterly EPS × 4
Quarterly Performance Comparison (₹ Cr)
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
8,828
8,038
8,572
9.83%
2.99%
EBITDA
2,010
2,076
2,174
-3.18%
-7.54%
PAT
1,337
1,342
1,410
-0.37%
-5.18%
EPS (₹)
16.14
15.05
16.99
7.24%
-5.00%
Annualised EPS (Quarterly × 4): ₹64.56
EBITDA softness and PAT stagnation suggest margin pressure, not revenue weakness. This is classic pharma behaviour: pricing pressure meets compliance costs, margins blink first. Revenue, however, keeps marching forward.
Do you prefer margin stability or revenue momentum in pharma? Choose your fighter.
5. Valuation Discussion – Fair Value, Not Fantasy
P/E Method
CMP: ₹1,180
Annualised EPS: ₹64.56
Implied P/E: 18.3x
Using a reasonable P/E range of 16x–20x:
Fair Value Range: ₹1,030 – ₹1,290
EV/EBITDA Method
EV: ₹1,02,336 Cr
EBITDA (TTM): ₹8,454 Cr
EV/EBITDA: 12.1x
Using 10x–13x range:
Fair Value Range broadly aligns with ₹1,050 – ₹1,350
DCF (Simplified)
Assuming:
Revenue growth: low double digits
Stable margins
Conservative terminal growth
DCF doesn’t scream undervaluation, but it doesn’t scream bubble either.
Fair Value Range (Educational Only): ₹1,030 – ₹1,350 This fair value
